2025

Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform [...]

New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. OraTech will have global marketing rights to Oramed's [...]